Clinical Trials · NCT02237053

Effects of Glucagon Administration on Energy Expenditure

CompletedPhase 1Octreotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
AdventHealth Translational Research Institute
Enrollment
6
Start date
Sep 2014
Locations
1 site, United States
Primary endpoint
Measure of energy expenditure
View Octreotide compound reference